Monitoring rituximab in autoimmune diseases

This study follows patients with ANCA-associated vasculitis (a rare autoimmune disease affecting blood vessels) who receive rituximab, a medication that depletes certain immune cells. Researchers want to understand how the immune system recovers over time and whether this helps predict disease flares or relapses.

This trial tests a new treatment (AB-101) combined with rituximab for people with certain autoimmune diseases like rheumatoid arthritis, pemphigus vulgaris, vasculitis, or lupus. It is for those who have not had success with standard therapies.

This study tests whether a lower dose (200 mg) of rituximab given every 6 months is effective for maintaining control of rheumatoid arthritis. It is for people who are already on rituximab maintenance therapy and have low to moderate disease activity.

This trial compares two ways to reduce the amount of rituximab you take: one that gradually gives it less often based on time, and another that only gives it when your disease flares up. The goal is to see which approach keeps your arthritis under control while using less medication.

This trial aims to find out if a simple blood test (biomarker) can show whether a lower dose of rituximab will work for people with rheumatoid arthritis. If successful, it could help patients maintain good results with less medicine and fewer side effects.

This Phase 3 study tests rituximab, an immune-focused medicine, for people with a first episode or relapse of psychosis who have specific brain-targeting autoantibodies in their blood. It may help calm symptoms by changing how the immune system contributes to the illness.